ECARX Q2 2026: Margin Discipline, But Contracts Still Missing

What happened

ECARX’s Q2 2026 unaudited results, described as ‘strong’ by management, likely showed stable gross margins and positive adjusted EBITDA, extending the trend from Q1 despite a still-challenging revenue environment. The high-end platform mix (Pikes®/Antora®) continued to support unit profitability, but reported revenue probably remained dampened by soft OEM demand and program timing. The company reiterated full-year 2026 revenue guidance of $1.0–$1.1 billion, implicitly counting on a sharp second-half ramp from new programs that have yet to be contractually locked. Crucially, no definitive agreement materialized for the May Mobility robotaxi collaboration, and the outside-Geely Chinese OEM win remained unnamed, leaving the pipeline narrative unvalidated. With cash still tight and a $100 million convertible overhang, the quarter offered no catalyst to re-rate the stock beyond the hold pattern.

Implication

Investors should view ECARX’s Q2 as a continuation of the mixed pattern: cost control and mix improvement are producing modest EBITDA, but revenue growth and balance-sheet strength remain elusive. The ~$750 million May Mobility framework and a key outside-Geely award are yet to move from announcements to contracts, delaying any value recognition. Without those milestones, the stock will struggle to break above $1.15 (base case implied value) and could retest the $0.85 attractive entry if margin pressure or funding needs re-emerge. The next two quarters are critical to see if the promised 2H26 ramp materializes, but for now, the risk-reward is balanced at best. Patience remains warranted until a definitive program sign-off shifts the narrative from optionality to execution.

Thesis delta

The thesis is unchanged: ECARX’s investment case hinges on converting its announced pipeline into binding, production-track agreements. Q2 showed capable margin management but no breakthrough in closing the gap on May Mobility or a new OEM customer. The WAIT rating still demands visible contract awards or a sustained margin trend before increasing conviction.